Project Grant K23HL173659
Award Date
12/20/24
Completion Date
11/30/29
Dollars Obligated
$201K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is providing $1,147,992 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at advancing precision medicine for acute respiratory distress syndrome (ARDS) and sepsis. The key focus is on deeply phenotyping human samples to understand the functional immune response and pathogen drivers of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $480,990 to the University of Illinois for a research project focused on accelerating alveolar epithelial regeneration to treat acute respiratory distress syndrome (ARDS). The key objectives are to investigate the role of "aerocytes", a newly identified capillary endothelial cell population, in regulating alveolar...
This $607,952 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at the University of Pittsburgh to investigate indole metabolites as novel danger signals that activate regulated cell death pathways in lung epithelial cells, which may contribute to the pathogenesis of acute respiratory distress syndrome (ARDS). The key research objectives include...
This $782,362 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of TREK-1 potassium channels in acute respiratory distress syndrome (ARDS). The key objectives are to: 1) determine if ARDS decreases epithelial and endothelial TREK-1 levels, leading to cell membrane depolarization and calcium-dependent inflammation, and 2) evaluate if activating residual TREK-1...
This Project Grant award, identified as R01HL170118, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The award, totaling $495,159.00, will fund research to investigate the role of the protein CARMIL1 in regulating endothelial cell barrier function and its potential impact on acute respiratory distress syndrome (ARDS). The study, to be conducted by the University of Illinois, will use...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $189,000 to the University of Colorado-Denver to investigate the role of aldehyde dehydrogenase 2 (ALDH2) in pulmonary fibrosis following acute lung injury and acute respiratory distress syndrome (ARDS). The 2-year research project aims to elucidate the mechanisms by which ALDH2 impacts fibrogenesis in lung cells and evaluate the...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $188,740 to the University of Pittsburgh to conduct research on the impact of glycocalyx degradation on acute respiratory distress syndrome (ARDS) pathogenesis and outcomes. The research aims to: 1) estimate the attributable impact of glycocalyx degradation on ARDS patient outcomes, and 2) determine the longitudinal relationship between glycocalyx degradation...
This is a Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program. The $827,682 award will fund a comprehensive research project to develop advanced imaging techniques, including dynamic contrast-enhanced CT, dual-energy CT, and electrical impedance tomography, to characterize pulmonary perfusion and guide personalized treatment of acute respiratory distress...
This $186,408 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research to evaluate CD14 as a potential therapeutic target for acute respiratory distress syndrome (ARDS). The project aims to: 1) determine the effects of the CD14-blocking antibody IC14 on cellular targets through blood leukocyte RNA sequencing analysis, 2) examine the relationship between the CD14-pathway biomarker presepsin...
This Project Grant award of $775,992.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at the University of North Carolina at Chapel Hill to investigate the role of regulatory T cells (Tregs) and glucocorticoid signaling in the resolution of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The research aims to determine how glucocorticoid signaling through Tregs impacts their immunomodulatory and tissue...